RCA Settles $2M Federal Case Over Drug Control Violations

Recovery Centers of America Agrees to $2 Million Settlement for Controlled Substances and False Claims Violations

Recovery Centers of America (RCA), a major operator of drug and alcohol treatment facilities across Pennsylvania and Maryland, has agreed to pay $2 million to resolve federal allegations that the company violated controlled substance laws and submitted false claims to government health programs. The U.S. Attorney's Office for the Eastern District of Pennsylvania announced the settlement on December 10, 2025, bringing to a close a whistleblower case that exposed serious compliance failures at multiple RCA treatment centers.

What the Case Alleged

The lawsuit, filed under False Claims Act whistleblower provisions known as qui tam cases, alleged that RCA engaged in violations spanning multiple years and affecting two critical areas of federal law:

Controlled Substances Act Violations (2019-2024)

Between 2019 and 2024, Drug Enforcement Administration investigators conducted audits at RCA facilities in Pennsylvania and Maryland. The audits uncovered serious violations related to how the company handled controlled substances used in treatment programs, including at facilities in Devon and Capital Region. The allegations included unlawful dispensing of controlled substances, missing inventory that wasn't properly documented in company records, failure to maintain receipt records showing the number of containers and dates, prescriptions issued to "house stock" rather than named patients, and systematic recordkeeping failures that made it impossible for federal regulators to track how controlled drugs were being handled.

These types of violations carry particular weight because controlled substances require strict chain-of-custody documentation and inventory controls. The failures alleged in this case suggest that RCA may not have had adequate systems in place to prevent drug diversion—the term for controlled medications being funneled away from their intended medical purpose toward illegal use or sale.

False Claims Act Violations (2017-2019)

In a separate set of allegations, the government contended that between 2017 and 2019, RCA submitted false claims to federal health programs. This included billing for drug and alcohol treatment services that were either inadequate, not provided, or lacked proper documentation, particularly at facilities in Danvers and Westminster. The case involved claims submitted to the Federal Employees Health Benefits Program and Medicaid, meaning that patients covered by these government insurance programs may have received substandard care while the government paid for full treatment services.

False Claims Act violations carry significant consequences because they allow the government to recover not only the amount of fraudulent claims but also civil penalties. These cases serve as a deterrent against healthcare providers submitting claims for services that weren't properly provided or documented.

How the Case Was Discovered

The lawsuit was brought forward by a whistleblower who had direct knowledge of RCA's practices. The relator worked as an Outcomes Supervisor at RCA's King of Prussia, Pennsylvania headquarters, giving them insight into how the company operated across multiple facilities. Under False Claims Act provisions, private citizens with knowledge of fraud against the government can file lawsuits on behalf of the United States and receive a portion of any recovery.

The whistleblower's decision to come forward and cooperate with federal investigators proved crucial in uncovering the extent of the violations. In recognition of this role, the whistleblower will receive $230,000 from the settlement—a standard provision in qui tam cases that encourages individuals to report fraud they encounter in their workplaces.

Settlement Terms and What They Mean

RCA has agreed to pay a total of $2 million to resolve all allegations. The settlement breaks down as follows:

• $1 million to resolve Controlled Substances Act violations
• $1 million to resolve False Claims Act violations

The settlement does not include an admission of liability by RCA. The company stated the agreement addresses historical allegations related to services at its Danvers and Westminster locations, as well as DEA recordkeeping and other regulatory compliance matters at its Devon and Capital Region facilities, and chose to settle to avoid the costs and distraction of protracted litigation. This is a common feature of government settlements, allowing companies to resolve cases while maintaining that they didn't intentionally violate the law. The payment amount and the need for a settlement, however, indicate that federal prosecutors found sufficient evidence to support the allegations.

The settlement was handled through the U.S. District Court for the Eastern District of Pennsylvania and was negotiated by U.S. Attorney David Metcalf and the U.S. Attorney's Office, which enforces federal law in that judicial district.

Why This Matters for Consumers

This settlement carries important implications for patients who have received or may receive treatment at RCA facilities. Several consumer-protection issues are relevant:

Quality of Care Concerns

The allegations that RCA submitted false claims for inadequately documented services raise questions about whether patients covered by federal insurance programs received the full level of care they paid for. Drug and alcohol treatment requires careful monitoring, documentation, and adherence to treatment protocols. If RCA's recordkeeping was deficient, it suggests that proper care standards may not have been maintained.

Drug Diversion Risks

The Controlled Substances Act violations alleged in the case—particularly missing inventory and recordkeeping failures—indicate that RCA may not have had adequate safeguards to prevent controlled medications from being diverted. This is especially concerning in a treatment setting where patients may be vulnerable and where the proper handling of controlled substances is essential to safety.

Federal Insurance Protection

Patients covered by the Federal Employees Health Benefits Program or Medicaid may have unknowingly received services at RCA facilities where these violations were occurring. The settlement helps ensure that the government programs that insure these patients are compensated for any fraudulent claims, though this doesn't directly reimburse individual patients for any substandard care they may have received.

Looking Forward: Compliance and Oversight

Settlements like this one typically require the defendant to implement compliance measures going forward. While specific compliance requirements aren't detailed in the public announcement, such cases generally result in enhanced monitoring, improved recordkeeping systems, and oversight mechanisms to prevent future violations. These improvements could benefit future patients at RCA facilities.

The settlement also serves as a signal to other treatment providers about the importance of maintaining strict compliance with both controlled substances regulations and billing practices. Treatment facilities that operate with federal funding or serve federally insured patients must understand that violations can result in significant financial penalties. "Unlawful dispensing of controlled substances and billing for unprovided care endanger patients and defraud taxpayers," said Maureen Dixon, Special Agent in Charge of HHS-OIG.

What Affected Patients Should Know

If you or a family member received treatment at an RCA facility in Pennsylvania or Maryland during the periods mentioned in this case (particularly 2017-2024), you may want to review your records and insurance statements. While this settlement doesn't automatically provide compensation to individual patients, it documents that serious compliance failures occurred at these facilities.

Patients who believe they received inadequate care or who have concerns about their treatment experience can contact their state's health department or medical licensing board to file complaints. If you have questions about billing for treatment you received, you can contact your insurance provider or the appropriate government program (if you were covered by Medicaid or the Federal Employees Health Benefits Program).

This case underscores the importance of transparency and accountability in the healthcare industry, particularly in specialized treatment settings where vulnerable populations receive care.